In this article, we will list the 5 Most Promising Penny Stocks According to Wall Street Analysts. Please visit 10 Most Promising Penny Stocks According to Wall Street Analysts to see the extended list and the methodology behind it.

5. VinFast Auto Ltd. (NASDAQ:VFS)

Average Upside Potential: 77.51%

VinFast Auto Ltd. (NASDAQ:VFS) is one of the most promising penny stocks according to Wall Street analysts. On June 1, VinFast, Autobrains, and NVIDIA announced a collaboration to develop a Level 4 autonomous driving program tailored specifically for Southeast Asia’s complex traffic environments. Built on the NVIDIA DRIVE Hyperion 10 platform, the project utilizes Autobrains’ “Agentic AI,” which employs specialized AI agents to handle real-world driving tasks more efficiently than traditional end-to-end models.

This partnership aims to overcome the industry’s persistent barriers to autonomy: high compute costs, excessive system complexity, and brittle performance. By using a modular architecture and Agentic AI, the companies plan to deliver advanced autonomous capabilities without the premium price tags that have previously hindered mass deployment in the region.

The initiative uses NVIDIA’s hardware foundation to accelerate development timelines and reduce integration efforts. For VinFast Auto Ltd. (NASDAQ:VFS), this program is a core component of its strategy to make smart electric vehicle technologies more accessible and scalable, ensuring reliable autonomous performance in dynamic urban settings while maintaining a cost-efficient path to market.

VinFast Auto Ltd. (NASDAQ:VFS) designs and manufactures electric vehicles. It offers electric scooters (e-scooters) and electric buses (e-buses). It provides an e-mobility ecosystem built around customers, community, and connectivity alongside new vehicle roll-out.

4. MannKind Corporation (NASDAQ:MNKD)

Average Upside Potential: 104.08%

MannKind Corporation (NASDAQ:MNKD) is one of the most promising penny stocks according to Wall Street analysts. On June 3, MannKind reached key milestones in its clinical program for nintedanib DPI, a dry powder inhalation therapy for idiopathic pulmonary fibrosis/IPF. The company has completed patient randomization for its US Phase 1b INFLO-1 trial and successfully enrolled the first participant in its global Phase 2 INFLO-2 study. Data from the INFLO-1 trial is expected in Q3 2026.

The nintedanib DPI program utilizes MannKind’s proprietary Technosphere technology to deliver medication directly to the lungs. By targeting the site of the disease, the company aims to maintain antifibrotic efficacy while minimizing the systemic side effects often associated with the currently approved oral form of nintedanib. This approach is designed to improve treatment tolerability, long-term adherence, and the potential for combination therapies in patients with IPF.

The Phase 2 INFLO-2 trial is a randomized, double-blind study designed to evaluate the safety, tolerability, and optimal dosing of nintedanib DPI in ~210 participants across 85 global sites. Following a 12-week treatment period, the study includes a 24-week open-label extension to assess secondary efficacy endpoints, including lung function and patient-reported outcomes, further defining the therapy’s potential as a new standard of care for the condition.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for those living with endocrine and orphan lung diseases.

3. Eve Holding Inc. (NYSE:EVEX)

Average Upside Potential: 107.10%

Eve Holding Inc. (NYSE:EVEX) is one of the most promising penny stocks according to Wall Street analysts. On May 5, Eve Holding reported a net loss of $68.8 million for Q1 2026, up from $48.8 million in the same period last year. As a pre-operational company, these results reflect intensified R&D expenses, which rose to $59.1 million. This increase is driven by ongoing eVTOL aircraft development, expanded supplier engagement, and critical engineering support provided by Embraer under its Master Service Agreement.

Despite the rise in R&D costs, the company saw a slight decrease in Selling, General & Administrative expenses to $7.2 million. The company’s total cash consumption reached $68.6 million for the quarter, or $57 million when adjusted for a deferred payment to Embraer. This higher spend aligns with the acceleration of design and development activities as the company scales its workforce and infrastructure.

Eve Holding Inc. (NYSE:EVEX) ended the quarter with a record liquidity position of $577.7 million, including $441.1 million in cash and financial investments and a new $150 million syndicated loan secured in January. This is sufficient to support the company’s planned operations and program investments through 2028 as it continues to develop its eVTOL aircraft and urban air mobility ecosystem.

Eve Holding Inc. (NYSE:EVEX) is a creator of urban air mobility solutions. It is engaged in the design and manufacturing of electric vertical take-off and landing (eVTOL) aircraft. It also provides eVTOL and support services, which include technical support, training, maintenance, data services, and ground handling.

2. OPKO Health Inc. (NASDAQ:OPK)

Average Upside Potential: 114.29%

OPKO Health Inc. (NASDAQ:OPK) is one of the most promising penny stocks according to Wall Street analysts. On April 30, OPKO Health amended its agreement with Nicoya Therapeutics to grant OPKO a 15% equity interest in the firm, deepening its partnership to commercialize RAYALDEE in Greater China. While the equity stake modifies the royalty and transfer price schedule, the original milestone structure remains intact, keeping OPKO eligible for up to $115 million in potential development, regulatory, and sales-based payments.

Nicoya, a specialist in the Chinese nephrology market, is currently working to bring RAYALDEE to patients suffering from secondary hyperparathyroidism associated with chronic kidney disease. With the treatment already approved in Macau, both companies are targeting further regulatory approvals across China and its related territories in 2027 to address the needs of an estimated 20 million adults affected by stage 3 or 4 chronic kidney disease in the region.

This collaboration uses OPKO Health Inc.’s (NASDAQ:OPK) integrated manufacturing and supply chain capabilities alongside Nicoya’s localized clinical and commercial expertise. Management noted that the expansion of this agreement aligns with the broader strategy to increase global patient access to RAYALDEE, representing a significant growth opportunity for both companies within the large and underserved Asian renal health market.

OPKO Health Inc. (NASDAQ:OPK) is a multinational biopharmaceutical and diagnostics company that discovers, develops, and commercializes pharmaceutical products and operates clinical laboratories. It focuses on treating serious diseases through products such as RAYALDEE and NGENLA, while also providing diagnostic services.

1. Alvotech (NASDAQ:ALVO)

Average Upside Potential: 135.51%

Alvotech (NASDAQ:ALVO) is one of the most promising penny stocks according to Wall Street analysts. On May 11, Alvotech announced the completion of a routine FDA surveillance inspection at its manufacturing facility in Reykjavik, Iceland. While the FDA issued a Form 483 at the conclusion of the visit on May 8, 2026, the company stated that it believes the observations are manageable and do not indicate significant issues with the site’s overall operations or compliance.

Management views the results as a validation of the facility’s current cGMP fundamentals and the effectiveness of improvements implemented over the past year. Consequently, the company remains on schedule to resubmit its relevant BLAs during Q2 2026.

Alvotech (NASDAQ:ALVO) maintains its outlook for achieving FDA approval for these BLAs within the 2026 calendar year. The company continues to focus on finalizing the necessary data compilation to support the upcoming regulatory submissions.

Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. The firm’s focus is on the development of its product candidates, with its operations divided into the following geographical segments: Europe, North America, Asia, and Other.

READ NEXT: 10 Best Low Priced Stocks to Buy for the Next 3 Years and 12 Best Low Priced Growth Stocks to Invest In Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.